This study is comparing Osimertinib and Bevacizumab vs Osimertinib alone as first-line treatment for patients with metastatic EGFR mutant Non-Small Cell Lung Cancer (NSCLC). You must be diagnosed with stage 3 or 4 NSCLC.
Contact phoneTracy Bellefeuil | 517.364.2835
Principal investigatorDr. Gordan Srkalovic, MD, PhD
Trial SubCategoryNon-Small Cell Lung